PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-5.33%
Cash & equivalents declining -5.33% while AVXL's grows 1867.69%. Howard Marks would question why our liquidity is shrinking while competitor builds cash.
No Data
No Data available this quarter, please select a different quarter.
-5.33%
Below half of AVXL's 1867.69%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-5.33%
Below half of AVXL's 129.47%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-5.33%
Below half of AVXL's 125.91%. Michael Burry sees a potential red flag for stagnation or capital shortage.
-99.40%
Similar yoy growth to AVXL's -100.00%. Walter Schloss sees parallel payables strategy. Check top-line correlation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2.59%
Less than half of AVXL's 21.57%. David Dodd sees a more disciplined short-term liability approach.
11.04%
Higher Long-Term Debt Growth compared to AVXL's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
11.04%
Higher Total Non-Current Liabilities Growth compared to AVXL's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
6.71%
Less than half of AVXL's 21.57%. David Dodd sees far fewer liability expansions relative to competitor.
No Data
No Data available this quarter, please select a different quarter.
-2.35%
0.75-0.9x AVXL's -2.89%. Bill Ackman questions if competitor reinvests profits more robustly.
No Data
No Data available this quarter, please select a different quarter.
-0.00%
Less than half of AVXL's 2.41%. David Dodd notes simpler yoy equity changes vs. competitor.
-6.73%
Below half AVXL's -18.02%. Michael Burry sees potential underperformance in building shareholder capital.
-5.33%
Below half AVXL's 125.91%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
11.04%
Above 1.5x AVXL's 3.86%. Michael Burry sees a major jump. Investigate leverage rationale.
11.08%
Less than half of AVXL's -10.89%. David Dodd sees better deleveraging or stronger cash buildup than competitor.